The first oral small‐molecule inhibitor, erdafitinib, which targets FGFR3, was approved in 2019 for the Third‐line treatment of BC bearing susceptible FGFR2/3 mutations or for the second‐line treatment of locally advanced or metastatic BC following platinum‐based chemotherapy.160. Here, FGFR2 is linked to breast cancer.